.Nature Medicine, Posted online: thirteen September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized stage 3b/4 DESTINY-Breast12 research, trastuzumab deruxtecan (T-DXd) treatment of patients with HER2+ sophisticated bosom cancer cells as well as energetic or dependable brain metastases revealed constant intracranial task and wide spread efficacy of T-DXd.